Seasonal Allergic Rhinitis In Pediatric Subjects
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, Perennial
- Registration Number
- NCT00107757
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The purpose of this study is to determine if the investigational drug is effective and safe in children with seasonal allergic rhinitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 576
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Improvement in daily, reflective total nasal symptom scores after 2 weeks of treatment in subjects ages 6 to <12 years.
- Secondary Outcome Measures
Name Time Method Improvement in AM, pre-dose, instantaneous total nasal symptom scores after 2 weeks of treatment, overall evaluation of response to therapy after 2 weeks of treatment for subjects ages 6 to <12 years.
Trial Locations
- Locations (1)
GSK Investigational Site
🇺🇸Madison, Wisconsin, United States